PURPOSE: The goal of this study was to determine the frequency and clinical features of early treatment failure during induction chemotherapy before protocol radiation therapy for children with intermediate-risk rhabdomyosarcoma (RMS). PATIENTS AND METHODS: Patients with intermediate-risk RMS enrolled onto the Intergroup Rhabdomyosarcoma Study-IV and the Children's Oncology Group D9803 study were reviewed for an early treatment failure. Early failure was defined as failure caused by progressive disease, death as a result of progressive disease, or death as a result of other causes occurring fewer than 120 days from study entry. Patients with parameningeal site RMS with high-risk features who received radiation therapy at week 1 were excluded from analysis. Overall survival (OS) was estimated using the Kaplan-Meier method. Fisher's exact test was used to compare differences between groups. Cumulative incidence of progression was estimated. RESULTS: Of 916 patients, 20 (2.2%) were found to have an early disease progression and did not receive planned protocol radiotherapy. Three additional early failures resulted from treatment-related death without progression. Median time to failure was 48 days (range, 7 to 106 days). Nineteen (95%) of the 20 patients experienced progression at their primary site. Five-year OS was 32% (95% CI, 12% to 54%) for patients experiencing an early progression. CONCLUSION: A small proportion of patients with intermediate-risk RMS suffer an early failure as a result of early progression (2.2%) or treatment-related mortality (0.3%). The majority of patients with early progression had a local failure. Earlier radiotherapy could potentially improve outcome by preventing early local progression.
PURPOSE: The goal of this study was to determine the frequency and clinical features of early treatment failure during induction chemotherapy before protocol radiation therapy for children with intermediate-risk rhabdomyosarcoma (RMS). PATIENTS AND METHODS: Patients with intermediate-risk RMS enrolled onto the Intergroup Rhabdomyosarcoma Study-IV and the Children's Oncology Group D9803 study were reviewed for an early treatment failure. Early failure was defined as failure caused by progressive disease, death as a result of progressive disease, or death as a result of other causes occurring fewer than 120 days from study entry. Patients with parameningeal site RMS with high-risk features who received radiation therapy at week 1 were excluded from analysis. Overall survival (OS) was estimated using the Kaplan-Meier method. Fisher's exact test was used to compare differences between groups. Cumulative incidence of progression was estimated. RESULTS: Of 916 patients, 20 (2.2%) were found to have an early disease progression and did not receive planned protocol radiotherapy. Three additional early failures resulted from treatment-related death without progression. Median time to failure was 48 days (range, 7 to 106 days). Nineteen (95%) of the 20 patients experienced progression at their primary site. Five-year OS was 32% (95% CI, 12% to 54%) for patients experiencing an early progression. CONCLUSION: A small proportion of patients with intermediate-risk RMS suffer an early failure as a result of early progression (2.2%) or treatment-related mortality (0.3%). The majority of patients with early progression had a local failure. Earlier radiotherapy could potentially improve outcome by preventing early local progression.
Authors: W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: A S Pappo; J R Anderson; W M Crist; M D Wharam; P P Breitfeld; D Hawkins; R B Raney; R B Womer; D M Parham; S J Qualman; H E Grier Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: Carola A S Arndt; Julie A Stoner; Douglas S Hawkins; David A Rodeberg; Andrea A Hayes-Jordan; Charles N Paidas; David M Parham; Lisa A Teot; Moody D Wharam; John C Breneman; Sarah S Donaldson; James R Anderson; William H Meyer Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: Jeff M Michalski; Jane Meza; John C Breneman; Suzanne L Wolden; Fran Laurie; MaryAnn Jodoin; Beverly Raney; Moody D Wharam; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Megan Burke; James R Anderson; Simon C Kao; David Rodeberg; Stephen J Qualman; Suzanne L Wolden; William H Meyer; Philip P Breitfeld Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Dana L Casey; Yueh-Yun Chi; Sarah S Donaldson; Douglas S Hawkins; Jing Tian; Carola A Arndt; David A Rodeberg; Jonathan C Routh; Timothy B Lautz; Abha A Gupta; Torunn I Yock; Suzanne L Wolden Journal: Cancer Date: 2019-06-07 Impact factor: 6.860
Authors: Matthew M Ladra; Jackie D Szymonifka; Anita Mahajan; Alison M Friedmann; Beow Yong Yeap; Claire P Goebel; Shannon M MacDonald; David R Grosshans; Carlos Rodriguez-Galindo; Karen J Marcus; Nancy J Tarbell; Torunn I Yock Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Aaron C Spalding; Douglas S Hawkins; Sarah S Donaldson; James R Anderson; Elizabeth Lyden; Fran Laurie; Suzanne L Wolden; Carola A S Arndt; Jeff M Michalski Journal: Int J Radiat Oncol Biol Phys Date: 2013-11-01 Impact factor: 7.038
Authors: Ralph P Ermoian; John Breneman; David O Walterhouse; Yueh-Yun Chi; Jane Meza; James Anderson; Douglas S Hawkins; Andrea A Hayes-Jordan; David M Parham; Torunn I Yock; Sarah S Donaldson; Suzanne L Wolden Journal: Pediatr Blood Cancer Date: 2017-05-26 Impact factor: 3.167
Authors: Thomas E Merchant; David Hodgson; Nadia N I Laack; Suzanne Wolden; Danny J Indelicato; John A Kalapurakal Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Abby R Rosenberg; James R Anderson; Elizabeth Lyden; David A Rodeberg; Suzanne L Wolden; Simon C Kao; David M Parham; Carola Arndt; Douglas S Hawkins Journal: Eur J Cancer Date: 2013-12-18 Impact factor: 9.162